http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/list Mynewsdesk nyhetsfeed direkt från källan http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/list http://www.mynewsdesk.com/images/redesign/graphics/logos/logo-small.png 128 23 sv 15 Thu, 29 Nov 2012 15:03:19 +0100 -- New Oral Granule Formulation and Lower-Strength Tablets Available for New Indications -- http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/european-commission-approves-viread-r-for-hiv-1-infection-in-children-and-adolescents-and-for-chronic-hepatitis-b-in-adolescents-817711?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/european-commission-approves-viread-r-for-hiv-1-infection-in-children-and-adolescents-and-for-chronic-hepatitis-b-in-adolescents-817711?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gilead Thu, 29 Nov 2012 09:59:28 +0100 -- POSITRON Demonstrates Efficacy of a 12-Week All-Oral Regimen of Sofosbuvir Plus Ribavirin for Chronic Hepatitis C Patients who are Unable or Unwilling to Take Interferon -- http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-announces-sustained-virologic-response-rate-of-78-from-phase-3-study-of-sofosbuvir-for-genotype-2-3-hepatitis-c-infected-patients-817524?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-announces-sustained-virologic-response-rate-of-78-from-phase-3-study-of-sofosbuvir-for-genotype-2-3-hepatitis-c-infected-patients-817524?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gilead Fri, 23 Nov 2012 08:59:12 +0100 I oktober 2012 genomfördes en webbaserad enkät med syfte att kartlägga kunskapen och attityder om hiv bland allmänheten. Bland annat visar den att omkring 40 procent av dem som svarade hade gjort något för att få mer kunskaper om hiv de senaste åren. Den viktigaste källan till information var Internet. http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/ny-undersoekning-maanga-soeker-mer-kunskap-om-hiv-815732?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/ny-undersoekning-maanga-soeker-mer-kunskap-om-hiv-815732?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gilead Fri, 16 Nov 2012 09:57:26 +0100 -- Pivotal Data from Two Phase 3 Studies Highlight Stribild’s Sustained Efficacy, Safety and Tolerability Profile -- http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-s-once-daily-single-tablet-regimen-stribild-maintains-high-viral-suppression-through-two-years-of-therapy-among-treatment-naive-hiv-813507?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-s-once-daily-single-tablet-regimen-stribild-maintains-high-viral-suppression-through-two-years-of-therapy-among-treatment-naive-hiv-813507?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gilead Fri, 16 Nov 2012 09:55:30 +0100 -- STaR Study Findings Support Complera as an Important Single Tablet Regimen Option -- http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-s-complera-r-non-inferior-to-atripla-r-among-treatment-naive-hiv-patients-813505?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-s-complera-r-non-inferior-to-atripla-r-among-treatment-naive-hiv-patients-813505?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gilead Thu, 01 Nov 2012 14:19:19 +0100 -- Data Support Tenofovir Alafenamide Fumarate as Component of Future Single Tablet HIV Regimens -- http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-s-once-daily-novel-prodrug-for-the-treatment-of-hiv-meets-24-week-primary-objective-in-phase-2-study-809029?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-s-once-daily-novel-prodrug-for-the-treatment-of-hiv-meets-24-week-primary-objective-in-phase-2-study-809029?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gilead Tue, 28 Aug 2012 10:13:02 +0200 – Stribild is Gilead’s Third Single Tablet Regimen for the Treatment of HIV and the First to Contain an Integrase Inhibitor – http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/u-s-fda-approves-gilead-s-stribild-a-complete-once-daily-single-tablet-regimen-for-treatment-naive-adults-with-hiv-1-infection-788069?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/u-s-fda-approves-gilead-s-stribild-a-complete-once-daily-single-tablet-regimen-for-treatment-naive-adults-with-hiv-1-infection-788069?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gilead Tue, 24 Jul 2012 16:04:36 +0200 – First Agent Indicated for Uninfected Adults at High Risk of Acquiring HIV Through Sex – http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/u-s-food-and-drug-administration-approves-gilead-s-truvada-r-for-reducing-the-risk-of-acquiring-hiv-781263?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/u-s-food-and-drug-administration-approves-gilead-s-truvada-r-for-reducing-the-risk-of-acquiring-hiv-781263?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gilead Tue, 03 Jul 2012 09:36:37 +0200 Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or “boosting” agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing. http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-submits-new-drug-application-to-u-s-fda-for-boosting-agent-cobicistat-777397?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-submits-new-drug-application-to-u-s-fda-for-boosting-agent-cobicistat-777397?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gilead Fri, 29 Jun 2012 13:22:07 +0200 Elvitegravir Also a Component of Quad Single Tablet Regimen, Currently Under Regulatory Review for Patients New to Therapy http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-submits-new-drug-application-to-u-s-fda-for-hiv-integrase-inhibitor-elvitegravir-for-treatment-experienced-patients-776673?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-submits-new-drug-application-to-u-s-fda-for-hiv-integrase-inhibitor-elvitegravir-for-treatment-experienced-patients-776673?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gilead Wed, 20 Jun 2012 10:04:53 +0200 Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its Marketing Authorisation Application (MAA) for elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced patients, has been validated by the European Medicines Agency (EMA). http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/european-medicines-agency-validates-gilead-s-marketing-application-for-elvitegravir-for-treatment-of-hiv-infection-773910?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/european-medicines-agency-validates-gilead-s-marketing-application-for-elvitegravir-for-treatment-of-hiv-infection-773910?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gilead Thu, 24 May 2012 14:01:00 +0200 Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the Marketing Authorisation Application (MAA) for cobicistat, submitted on April 26, 2012, has been validated by the European Medicines Agency (EMA). http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-files-european-marketing-application-for-boosting-agent-cobicistat-765329?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-files-european-marketing-application-for-boosting-agent-cobicistat-765329?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gilead Fri, 11 May 2012 16:37:00 +0200 http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/fda-advisory-committee-supports-approv-al-of-gilead-s-truvada-r-for-reducing-the-risk-of-acquiring-hiv-761769?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/fda-advisory-committee-supports-approv-al-of-gilead-s-truvada-r-for-reducing-the-risk-of-acquiring-hiv-761769?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gilead Fri, 27 Apr 2012 14:24:00 +0200 - ATOMIC Data Demonstrate High Cure Rates in Genotype 1 Patients With 12 Weeks of Treatment - http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-announces-sustained-virologic-response-data-for-12-week-regimen-of-gs-7977-plus-pegylated-interferon-and-ribavirin-in-genotype-1-hepatitis-c-754835?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-announces-sustained-virologic-response-data-for-12-week-regimen-of-gs-7977-plus-pegylated-interferon-and-ribavirin-in-genotype-1-hepatitis-c-754835?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gilead Fri, 27 Apr 2012 14:23:00 +0200 - Interim Results Reported from ELECTRON and QUANTUM Studies - http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-announces-early-sustained-virologic-response-rates-for-gs-7977-plus-ribavirin-in-genotype-1-treatment-na-ive-hepatitis-c-patients-754834?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-announces-early-sustained-virologic-response-rates-for-gs-7977-plus-ribavirin-in-genotype-1-treatment-na-ive-hepatitis-c-patients-754834?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gilead Wed, 11 Apr 2012 08:54:11 +0200 -- Viread Now Available in an Oral Powder and Three Lower-Strength Tablets -- http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/u-s-food-and-drug-administration-approves-new-formulations-of-viread-r-for-use-by-children-living-with-hiv-749479?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/u-s-food-and-drug-administration-approves-new-formulations-of-viread-r-for-use-by-children-living-with-hiv-749479?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gilead Mon, 02 Apr 2012 14:51:41 +0200 http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/u-s-fda-accepts-new-drug-application-for-gilead-s-once-daily-single-tablet-quad-hiv-regimen-747659?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/u-s-fda-accepts-new-drug-application-for-gilead-s-once-daily-single-tablet-quad-hiv-regimen-747659?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gilead Mon, 02 Apr 2012 14:50:09 +0200 Gilead Sciences, Inc. (Nasdaq:GILD) announced today that the Marketing Authorisation Application (MAA) for the Quad single-tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults, submitted on November 24, 2011, has been validated by the European Medicines Agency (EMA). http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-files-european-marketing-application-for-the-quad-a-once-daily-single-tablet-regimen-for-the-treatment-of-hiv-infection-747658?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-files-european-marketing-application-for-the-quad-a-once-daily-single-tablet-regimen-for-the-treatment-of-hiv-infection-747658?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gilead Mon, 02 Apr 2012 09:06:24 +0200 Gilead Sciences, Inc. (Nasdaq: GILD) meddelade i dag att Eviplera® (emtricitabin/rilpivirin/tenofovirdisoproxil), en komplett behandling för HIV-1-infektion som tas som en tablett en gång dagligen, nu finns tillgänglig i Sverige och resten av Norden. http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gileads-nya-behandling-foer-hiv-1-infektion-som-tas-som-en-tablett-en-gaang-om-dagen-finns-nu-i-sverige-747446?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gileads-nya-behandling-foer-hiv-1-infektion-som-tas-som-en-tablett-en-gaang-om-dagen-finns-nu-i-sverige-747446?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gilead Mon, 26 Mar 2012 10:21:00 +0200 - If Approved, Product Would Represent First Antiretroviral Indicated to Reduce Risk of HIV Infection in Adults - http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-sciences-submits-supplemental-new-drug-application-to-u-s-food-and-drug-administration-for-truvada-r-for-reducing-the-risk-of-acquiring-hiv-745207?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/gilead/pressrelease/view/gilead-sciences-submits-supplemental-new-drug-application-to-u-s-food-and-drug-administration-for-truvada-r-for-reducing-the-risk-of-acquiring-hiv-745207?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Gilead